

12/14/2020

Addition of Bamlanivimab as Texas Medicaid Benefit

Background:

Bamlanivimab is currently available at no cost. On Dec. 3, 2020, Texas Medicaid added Bamlanivimab (Q0239) and administration of Bamlanivimab (M0239) as benefits in response to the COVID-19 Emergency Use Authorization (EUA). It is an allowable drug for dates of service on or after Nov. 9, 2020.

Key Details:

Administration of Bamlanivimab as an outpatient benefit is for people diagnosed with mild to moderate coronavirus disease (COVID-19) with a diagnosis of U07.1, are 12 years of age and older, weigh at least 40 kg, and are at a high risk of progressing to severe COVID-19 or requiring hospitalization. Texas Medicaid will reimburse providers only for the administration of Bamlanivimab at this time, following CMS guidance.

Contact:

vdp-cad@hhsc.state.tx.us

Type: Informational

To: CHIP; STAR; STAR+PLUS; STARHEALTH; STAR_KIDS

From: VDP